GREPNSEM2601 - CME/CMLE - Optimizing NSCLC Biomarker Testing: Effective Real-World Solutions

Course Description

Optimizing NSCLC Biomarker Testing: Effective Real-World Solutions

Activity Description:

This enduring recording from the ASCP 2025 Annual Meeting focuses on optimizing non-small cell lung cancer (NSCLC) biomarker testing. The session reviews emerging biomarkers and evolving targeted therapy considerations, clarifies the roles of key testing modalities (e.g., IHC, ISH, and NGS), and highlights practical strategies to improve tissue stewardship, specimen adequacy, and pre-analytic processes to support timely, appropriate, and equitable testing across clinical settings.

Course topics include:

NSCLC biomarker testing overview

HER2 (ERBB2) and MET/c-Met in NSCLC

Testing methods: IHC, ISH (FISH/CISH), and NGS

Specimen workflow and tissue stewardship

Target Audience

This activity has been designed to meet the educational needs of pathologists and laboratory professionals.   

Faculty/Authors:

Ying-Chun Lo, M.D., Ph.D., Associate Professor and Consultant
Divisions of Anatomic Pathology and Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology
Mayo Clinic, Rochester, MN

Mamatha Chivukula, MD, FASCP
Sutter Health,
San Francisco, California

Jefree Schulte, MD
Associate Professor CHS, Director of Surgical Pathology
University of Wisconsin, Department of Pathology and Laboratory Medicine, Madison, Wisconsin.

Joseph Kim, MD, MPH, MBA, FACHE
President, Q Synthesis LLC, Langhorne, PA

Physician Competencies:
Patient Care, Medical Knowledge.

Credit Designation Statement

The ASCP designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ASCP designates this activity for a maximum of 1.0 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.

Method of Participation
To complete the activity and receive credit, the participant must participate in the online activity. CME certificates will be provided online.  

Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

Review the Technical Considerations.
Click Go to Content and click the first module of the course.
Complete the Demographic Survey.
Complete the Pre-Test.
Review the Educational Activity.
Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
Submit the course Evaluation.
Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosures

Technical Considerations

Release Dates: 2/9/2026
Review Date:
Expiration Date: 2/9/2029

Course Objectives

Upon completion of this activity, you will be able to:

Discuss the latest research in new and emerging biomarkers for NSCLC
Prepare for potential changes to biomarker testing workflows as new therapies for patients with advanced NSCLC emerge
Outline the role of different HER2 testing methods in NSCLC to identify overexpression, amplification, and mutations
Apply current practice guidelines for biomarker testing in patients with NSCLC
Optimize NSCLC specimen protocols to ensure sufficient sample sizes for biomarker testing

Summary

Availability:

On-Demand

Credit Offered:

1 CME/CMLE Credit